CR10583A - Derivados de 1-(-d glucopiranosil)-3-(4-ciclopropilfenilmetil)-4-halogeno indol y uso de los mismos como inhibidores de los transportadores de glucosa dependientes de sodio - Google Patents

Derivados de 1-(-d glucopiranosil)-3-(4-ciclopropilfenilmetil)-4-halogeno indol y uso de los mismos como inhibidores de los transportadores de glucosa dependientes de sodio

Info

Publication number: CR10583A
Authority: CR; Costa Rica
Prior art keywords: cyclopropylpenhylmethyl; glucopiranosil; indol; conveyors; inhibitors
Prior art date: 2006-07-27

Application number

CR10583A

Other languages

English (en)

Inventor

Nomura Sumihiro

Sakamaki Shigeki

Original Assignee

Mitsubishi Tanabe Pharma Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-07-27

Filing date

2009-01-26

Publication date

2009-06-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38515468&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR10583(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-01-26 Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp

2009-06-05 Publication of CR10583A publication Critical patent/CR10583A/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Molecular Biology (AREA)
Neurology (AREA)
Genetics & Genomics (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Emergency Medicine (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Dermatology (AREA)
Child & Adolescent Psychology (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)

CR10583A 2006-07-27 2009-01-26 Derivados de 1-(-d glucopiranosil)-3-(4-ciclopropilfenilmetil)-4-halogeno indol y uso de los mismos como inhibidores de los transportadores de glucosa dependientes de sodio CR10583A (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US82060406P	2006-07-27	2006-07-27
US88617807P	2007-01-23	2007-01-23

Publications (1)

Publication Number	Publication Date
CR10583A true CR10583A (es)	2009-06-05

Family

ID=38515468

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CR10583A CR10583A (es)	2006-07-27	2009-01-26	Derivados de 1-(-d glucopiranosil)-3-(4-ciclopropilfenilmetil)-4-halogeno indol y uso de los mismos como inhibidores de los transportadores de glucosa dependientes de sodio

Country Status (31)

Country	Link
US (1)	US7851617B2 (es)
EP (1)	EP2049557B1 (es)
JP (1)	JP5102294B2 (es)
KR (1)	KR101179312B1 (es)
CN (1)	CN101501053B (es)
AR (1)	AR062111A1 (es)
AT (1)	ATE501159T1 (es)
AU (1)	AU2007277662B2 (es)
BR (1)	BRPI0715369A2 (es)
CA (1)	CA2658116C (es)
CL (1)	CL2007002197A1 (es)
CO (1)	CO6150170A2 (es)
CR (1)	CR10583A (es)
DE (1)	DE602007013056D1 (es)
DK (1)	DK2049557T3 (es)
EA (1)	EA016819B1 (es)
GT (1)	GT200900014A (es)
HN (1)	HN2009000161A (es)
IL (1)	IL196267A0 (es)
JO (1)	JO2681B1 (es)
MX (1)	MX2009000995A (es)
MY (1)	MY145106A (es)
NO (1)	NO20085337L (es)
NZ (1)	NZ574072A (es)
PE (1)	PE20080522A1 (es)
PL (1)	PL2049557T3 (es)
PT (1)	PT2049557E (es)
TW (1)	TWI418556B (es)
UA (1)	UA92100C2 (es)
UY (1)	UY30506A1 (es)
WO (1)	WO2008013322A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2099791B1 (en) *	2006-12-04	2012-11-21	Janssen Pharmaceutica, N.V.	Thienyl-containing glycopyranosyl derivatives as antidiabetics
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EA020209B1 (ru)	2007-09-10	2014-09-30	Янссен Фармацевтика Н.В.	Способ получения соединений, применимых в качестве ингибиторов натрийзависимого переносчика глюкозы
CL2008003653A1 (es) *	2008-01-17	2010-03-05	Mitsubishi Tanabe Pharma Corp	Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
WO2009117421A2 (en) *	2008-03-17	2009-09-24	Kalypsys, Inc.	Heterocyclic modulators of gpr119 for treatment of disease
PT2334687E (pt)	2008-08-28	2012-04-13	Pfizer	Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
US9056850B2 (en) *	2008-10-17	2015-06-16	Janssen Pharmaceutica N.V.	Process for the preparation of compounds useful as inhibitors of SGLT
US20110009347A1 (en) *	2009-07-08	2011-01-13	Yin Liang	Combination therapy for the treatment of diabetes
ES2416459T3 (es)	2009-07-10	2013-08-01	Janssen Pharmaceutica, N.V.	Procedimiento de cristalización para 1-( -D-glucopiranosil)-4-metil-3-[5-(4-fluorofenil)-2-tienilmetil]benceno
CN102597770B (zh)	2009-09-15	2016-08-10	詹森药业有限公司	α-甲基葡萄糖苷(AMG)作为葡萄糖吸收和排泄的指示剂的用途
AU2010306797B2 (en) *	2009-10-14	2014-11-27	Janssen Pharmaceutica Nv	Process for the preparation of compounds useful as inhibitors of SGLT2
US8394772B2 (en)	2009-10-20	2013-03-12	Novartis Ag	Glycoside derivative and uses thereof
KR101426180B1 (ko)	2009-11-02	2014-07-31	화이자 인코포레이티드	디옥사-비시클로［3.2.1］옥탄-2,3,4-트리올 유도체
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
DK2568988T3 (en)	2010-05-11	2016-08-22	Janssen Pharmaceutica Nv	Pharmaceutical formulations comprising 1- (BETA-D-glucopyranosyl) -2-THIENYLMETHYLBENZEN derivatives as inhibitors of SGLT
WO2011157827A1 (de)	2010-06-18	2011-12-22	Sanofi	Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
FR2969614A1 (fr) *	2010-12-28	2012-06-29	Sanofi Aventis	Nouveaux derives de pyrimidinones, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
HRP20170119T1 (hr) *	2010-12-28	2017-03-24	Sanofi	Novi derivati pirimidina, njihovo pripremanje, te njihova farmaceutska uporaba kao inhibitora akt (pkb) fosforilacije
PT2697218T (pt)	2011-04-13	2016-07-13	Janssen Pharmaceutica Nv	Processo para preparação de compostos úteis como inibidores da sglt2
TWI542596B (zh)	2011-05-09	2016-07-21	健生藥品公司	（２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
JP2014516038A (ja) *	2011-05-20	2014-07-07	ヤンセンファーマシューティカエヌ．ベー．	Ｓｇｌｔ−２の阻害物質として有用な化合物の調製プロセス
WO2012162115A2 (en) *	2011-05-20	2012-11-29	Janssen Pharmaceutica Nv	Process for the preparation of compounds useful as inhibitors of sglt-2
WO2013037390A1 (en)	2011-09-12	2013-03-21	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en)	2011-09-27	2013-04-04	Sanofi	6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
TW201335176A (zh) *	2011-12-15	2013-09-01	Nat Health Research Institutes	新穎醣苷化合物
TWI633113B (zh)	2013-10-17	2018-08-21	美國禮來大藥廠	新穎脲化合物
JO3298B1 (ar) *	2013-11-01	2018-09-16	Lilly Co Eli	مشتقات جليكوبيرانوسيل-مستبدل و اندول-يوريا و استعمالاتهم كمثبطات sglt
US20170071970A1 (en)	2015-09-15	2017-03-16	Janssen Pharmaceutica Nv	Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
JP7137318B2 (ja) *	2018-02-22	2022-09-14	オルガノ株式会社	被処理液の精製方法
CN115772163B (zh) *	2022-12-09	2025-07-22	中国科学院成都生物研究所	吲哚糖苷类化合物及吡咯糖苷类化合物及合成方法与应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2102591C (en) *	1992-11-12	2000-12-26	Kenji Tsujihara	Hypoglycemic agent
US5731292A (en) *	1992-11-12	1998-03-24	Tanabe Seiyaku Co., Ltd.	Dihydrochalcone derivatives which are hypoglycemic agents
US5830873A (en) *	1994-05-11	1998-11-03	Tanabe Seiyaku Co., Ltd.	Propiophenone derivative and a process for preparing the same
US6515117B2 (en)	1999-10-12	2003-02-04	Bristol-Myers Squibb Company	C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en)	1999-10-12	2006-02-21	Bristol Myers Squibb Co	C-aryl glucoside SGLT2 inhibitors
US6627611B2 (en) *	2000-02-02	2003-09-30	Kotobuki Pharmaceutical Co Ltd	C-glycosides and preparation of thereof as antidiabetic agents
JP4456768B2 (ja)	2000-02-02	2010-04-28	壽製薬株式会社	Ｃ−配糖体を含有する薬剤
TR200202200T2 (tr)	2000-03-17	2002-12-23	Kissei Pharmaceutical Co., Ltd.	Glükopiranosiloksibenzilbenzen türevleri, bu türevleri ihtiva eden tıbbi bileşimler ve türevlerin hazırlanması için ara-maddeler.
US6555519B2 (en)	2000-03-30	2003-04-29	Bristol-Myers Squibb Company	O-glucosylated benzamide SGLT2 inhibitors and method
US6683056B2 (en)	2000-03-30	2004-01-27	Bristol-Myers Squibb Company	O-aryl glucoside SGLT2 inhibitors and method
DE60138768D1 (de)	2000-12-28	2009-07-02	Kissei Pharmaceutical	Glucopyranosylpyrazolderivate und deren verwendung in arzneimitteln
TW593329B (en)	2001-02-26	2004-06-21	Kissei Pharmaceutical	Glucopyranosyloxypyrazole derivatives and pharmaceutical uses thereof
EP1364958B1 (en)	2001-02-27	2010-09-08	Kissei Pharmaceutical Co., Ltd.	Glycopyranosyloxypyrazole derivatives and medicinal use thereof
US6936590B2 (en) *	2001-03-13	2005-08-30	Bristol Myers Squibb Company	C-aryl glucoside SGLT2 inhibitors and method
EP1385856B1 (en)	2001-04-11	2006-02-22	Bristol-Myers Squibb Company	Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
WO2002088157A1 (fr)	2001-04-27	2002-11-07	Ajinomoto Co., Inc.	Derives pyrazolyl-o-glycoside n-substitues et medicament contre le diabete en contenant
JP4115105B2 (ja)	2001-07-02	2008-07-09	協和醗酵工業株式会社	ピラゾール誘導体
JPWO2003011880A1 (ja)	2001-07-31	2004-11-18	キッセイ薬品工業株式会社	グルコピラノシルオキシベンジルベンゼン誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
EP1432720A1 (en)	2001-09-05	2004-06-30	Bristol-Myers Squibb Company	O-pyrazole glucoside sglt2 inhibitors and method of use
US6562791B1 (en) *	2002-03-29	2003-05-13	Council Of Scientific And Industrial Research	Glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof
DE10231370B4 (de)	2002-07-11	2006-04-06	Sanofi-Aventis Deutschland Gmbh	Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
TWI254635B (en)	2002-08-05	2006-05-11	Yamanouchi Pharma Co Ltd	Azulene derivative and salt thereof
EP1541578A1 (en)	2002-08-09	2005-06-15	Taisho Pharmaceutical Co., Ltd	Process for selective production of aryl 5-thio-beta-d-aldohexopyranosides
WO2004019958A1 (ja)	2002-08-27	2004-03-11	Kissei Pharmaceutical Co., Ltd.	ピラゾール誘導体、それを含有する医薬組成物及びその医薬用途
DE10258008B4 (de)	2002-12-12	2006-02-02	Sanofi-Aventis Deutschland Gmbh	Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258007B4 (de) *	2002-12-12	2006-02-09	Sanofi-Aventis Deutschland Gmbh	Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
EP1980560B1 (en)	2003-03-14	2011-05-25	Astellas Pharma Inc.	C-glycoside derivatives for the treatment of diabetes
EP1679966A4 (en) *	2003-08-01	2009-05-27	Janssen Pharmaceutica Nv	SUBSTITUTED BENZIMIDAZOLE, BENZOTRIAZOL AND BENZIMIDAZOLON-O-GLUCOSIDES
UA86042C2 (en) *	2003-08-01	2009-03-25	Янссен Фармацевтика Н.В.	Substituted indazole-o-glucosides
SG130189A1 (en) *	2003-08-01	2007-03-20	Janssen Pharmaceutica Nv	Substituted indole-o-glucosides
WO2005011592A2 (en) *	2003-08-01	2005-02-10	Janssen Pharmaceutica N.V.	Substituted indazole-o-glucosides
CA2549015A1 (en) *	2003-08-01	2005-02-10	Janssen Pharmaceutica N.V.	Substituted fused heterocyclic c-glycosides
EP2896397B2 (en)	2003-08-01	2020-10-07	Mitsubishi Tanabe Pharma Corporation	Novel compounds having inhibitory activity against sodium-dependant glucose transporter
CA2581922A1 (en)	2004-09-29	2006-04-06	Kissei Pharmaceutical Co., Ltd.	1-(.beta.-d-glycopyranosyl)-3-substituted nitrogenous heterocyclic compound, medicinal composition containing the same, and medicinal use thereof
AR053329A1 (es) *	2005-01-31	2007-05-02	Tanabe Seiyaku Co	Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
JP2008050353A (ja) *	2006-07-27	2008-03-06	Mitsubishi Tanabe Pharma Corp	医薬組成物

2007
- 2007-07-11 TW TW096125166A patent/TWI418556B/zh not_active IP Right Cessation
- 2007-07-25 UY UY30506A patent/UY30506A1/es unknown
- 2007-07-25 JO JO2007306A patent/JO2681B1/en active
- 2007-07-26 PE PE2007000981A patent/PE20080522A1/es not_active Application Discontinuation
- 2007-07-26 AR ARP070103316A patent/AR062111A1/es unknown
- 2007-07-26 US US11/878,760 patent/US7851617B2/en not_active Expired - Fee Related
- 2007-07-26 CL CL200702197A patent/CL2007002197A1/es unknown
- 2007-07-27 MX MX2009000995A patent/MX2009000995A/es active IP Right Grant
- 2007-07-27 UA UAA200901760A patent/UA92100C2/uk unknown
- 2007-07-27 AU AU2007277662A patent/AU2007277662B2/en not_active Ceased
- 2007-07-27 MY MYPI20090277A patent/MY145106A/en unknown
- 2007-07-27 KR KR1020097004110A patent/KR101179312B1/ko not_active Expired - Fee Related
- 2007-07-27 DK DK07791887.8T patent/DK2049557T3/da active
- 2007-07-27 DE DE602007013056T patent/DE602007013056D1/de active Active
- 2007-07-27 PL PL07791887T patent/PL2049557T3/pl unknown
- 2007-07-27 PT PT07791887T patent/PT2049557E/pt unknown
- 2007-07-27 EA EA200970161A patent/EA016819B1/ru not_active IP Right Cessation
- 2007-07-27 EP EP07791887A patent/EP2049557B1/en active Active
- 2007-07-27 AT AT07791887T patent/ATE501159T1/de active
- 2007-07-27 CA CA2658116A patent/CA2658116C/en not_active Expired - Fee Related
- 2007-07-27 BR BRPI0715369-4A patent/BRPI0715369A2/pt not_active IP Right Cessation
- 2007-07-27 NZ NZ574072A patent/NZ574072A/en not_active IP Right Cessation
- 2007-07-27 WO PCT/JP2007/065213 patent/WO2008013322A1/en not_active Ceased
- 2007-07-27 JP JP2009521499A patent/JP5102294B2/ja not_active Expired - Fee Related
- 2007-07-27 CN CN2007800277313A patent/CN101501053B/zh not_active Expired - Fee Related
2008
- 2008-12-19 NO NO20085337A patent/NO20085337L/no not_active Application Discontinuation
- 2008-12-30 IL IL196267A patent/IL196267A0/en not_active IP Right Cessation
2009
- 2009-01-22 GT GT200900014A patent/GT200900014A/es unknown
- 2009-01-26 HN HN2009000161A patent/HN2009000161A/es unknown
- 2009-01-26 CR CR10583A patent/CR10583A/es unknown
- 2009-01-27 CO CO09006937A patent/CO6150170A2/es unknown

Also Published As

Publication number	Publication date
UY30506A1 (es)	2008-01-31
EA016819B1 (ru)	2012-07-30
PT2049557E (pt)	2011-05-05
JP5102294B2 (ja)	2012-12-19
EA200970161A1 (ru)	2009-06-30
CN101501053A (zh)	2009-08-05
CL2007002197A1 (es)	2008-02-15
CN101501053B (zh)	2012-10-03
PL2049557T3 (pl)	2011-07-29
WO2008013322A1 (en)	2008-01-31
US20080027122A1 (en)	2008-01-31
CA2658116A1 (en)	2008-01-31
BRPI0715369A2 (pt)	2013-06-18
UA92100C2 (uk)	2010-09-27
DK2049557T3 (da)	2011-06-14
MY145106A (en)	2011-12-30
ATE501159T1 (de)	2011-03-15
HN2009000161A (es)	2011-05-25
MX2009000995A (es)	2009-02-04
AU2007277662A1 (en)	2008-01-31
JP2009544693A (ja)	2009-12-17
GT200900014A (es)	2010-02-09
EP2049557B1 (en)	2011-03-09
KR20090040356A (ko)	2009-04-23
JO2681B1 (en)	2013-03-03
US7851617B2 (en)	2010-12-14
DE602007013056D1 (de)	2011-04-21
CA2658116C (en)	2011-07-19
AR062111A1 (es)	2008-10-15
AU2007277662B2 (en)	2011-02-03
NO20085337L (no)	2009-04-24
PE20080522A1 (es)	2008-06-13
EP2049557A1 (en)	2009-04-22
NZ574072A (en)	2011-05-27
CO6150170A2 (es)	2010-04-20
IL196267A0 (en)	2009-09-22
TW200811149A (en)	2008-03-01
TWI418556B (zh)	2013-12-11
KR101179312B1 (ko)	2012-09-03

Publication	Publication Date	Title
CR10583A (es)	2009-06-05	Derivados de 1-(-d glucopiranosil)-3-(4-ciclopropilfenilmetil)-4-halogeno indol y uso de los mismos como inhibidores de los transportadores de glucosa dependientes de sodio
CR10743A (es)	2009-06-05	Derivados de azaadamantano y metodos de uso de los mismos
BRPI0810524A2 (pt)	2014-10-21	Derivado de (aza)indol e uso do mesmo para propósitos médicos
CY1120741T1 (el)	2019-12-11	Θεραπεια οζωδους σκληρυνσης
BRPI0810522A2 (pt)	2014-10-21	Mimétricos diazo bicíclicos de smac e uso dos mesmos.
BRPI0720625A2 (pt)	2014-03-25	Derivados de indol de 4,5-anel anulados e métodos de uso dos mesmos
MA28824B1 (fr)	2007-08-01	Derives de pyrimidine
BRPI0809346A2 (pt)	2014-10-07	Compostos derivados substituídos de imidazopiridina e composição farmacêutica contendo os mesmos
BRPI0815811A2 (pt)	2015-02-18	Derivados de indol substituído e métodos de uso dos mesmos
ATE415400T1 (de)	2008-12-15	Pyrazolopyridinderivate
MA28813B1 (fr)	2007-08-01	Derives de pyrimidine
BRPI0720124A2 (pt)	2014-03-04	Composições farmacêuticas e seus métodos de uso.
EP4125244C0 (en)	2025-01-01	HASH BASED MULTIHOSTING
DE602005026867D1 (de)	2011-04-21	Entzündungshemmende indol-derivate
EP1896395A4 (en)	2010-12-01	MODIFIED DERIVATIVES OF MALONATE
DK1957492T3 (da)	2011-02-28	Substituerede bicykliske pyrimidonderivater
EP1731506A4 (en)	2009-12-09	5-HYDROXYINDOL-3-CARBOXYLATE DERIVATIVES AND THEIR USE
BRPI0813457A2 (pt)	2014-12-23	Composto de organoenxofre contendo halogênio e uso do mesmo
DE602006010581D1 (de)	2009-12-31	4-phenyl-6-substituierte pyrimidin-2-carbonitrilderivate
BRPI0812909A2 (pt)	2014-12-09	Derivados de guanina policíclica e métodos de uso dos mesmos.
ATE485294T1 (de)	2010-11-15	Azaindol-2-carboxamid-derivate
FR2902426B1 (fr)	2008-09-05	Derives de cinnamoyl-piperazine
EP1961753A4 (en)	2009-11-25	PYRAZOLOPYRIMIDINONE DERIVATIVES, THEIR PREPARATION AND THEIR USE
ATE527255T1 (de)	2011-10-15	Aryl-isoxazol-4-yl-imidazol-derivate
BRPI0808172A2 (pt)	2014-11-04	Compostos heterocíclicos, composições compreendendo-os e métodos de seu uso.